MARK2 and neoplasm: Sorafenib, as a multi-target, multi-kinase inhibitor, both suppresses tumor proliferation by inhibiting serine/threonine kinases and blocking the RAF/MEK/ERK pathway and prevents tumor angiogenesis by inhibiting vascular endothelial growth factor receptors 1–3, platelet-derived growth factor receptor β, FMS-like tyrosine kinase 3, serine/threonine kinases (c-RAF and b-RAF), and epithelial growth factor receptor, thereby suppressing cancer growth and metastasis.